News

A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.

Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2022.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!

On April 20, the UK National Osteoporosis Guideline Group released updated guidance for the diagnosis, prevention, and treatment of osteoporosis, which has received endorsements from the IOF and ESCEO.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

As quality of life (QoL) in patients with psoriatic arthritis (PsA) is significantly lower when compared with patients with psoriasis, one of the main goals of treating PsA is improving QoL.

Infants born to mothers with autoimmune disease had a 16% higher risk of being diagnosed with a mental disorder compared with those who were not prenatally exposed to maternal autoimmune diseases.

Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.

An analysis of data from a 5000-patient cohort suggests use of NSAIDs was associated with a detrimental effect on the benefit of clodronate on reducing risk of fracture among older women.

Disease flares in systemic lupus erythematosus are associated with damage. However, the impact of flares on health-related quality of life have not been analyzed.

COVID-19 vaccines and drugs for rheumatoid arthritis (RA) don’t always mix well. How much do you know about how RA medications impact the immune response generated by COVID-19 vaccines?

White a treat-to-target strategy is an important part of managing patients with rheumatoid arthritis, a more controlled implementation with closer follow-up appointments and patient education yielded better outcomes.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 16, 2022.

Guidelines lack clear recommendations for osteoporosis management and fall prevention, which may be due to a lack of evidence in the literature.

Understanding the differences between sexes regarding PsA treatment may change the management of PsA in male and female patients and improve outcomes.

Investigators address the need for understanding surrounding the relationship between poor bone health and patients who are hemophilia carriers and those with von Willebrand disease.

“Although the achievement of treatment targets has been associated with improved quality of life and slower disease progression, patients may still experience symptoms and a burden of disease,” investigators stated.

Health-related quality of life and treatment satisfaction are often used to improve treatment outcomes as well as clinical care.

“Understanding the drivers of this increased risk in women with gout warrants further investigation in larger datasets," investigators stated.

Dietary counseling could play an important role in the treatment of patients with psoriatic arthritis, contributing to better disease activity control.

“There are no tailored age-specific treatment guidelines, and older adults are less likely to receive aggressive therapy for reasons of polypharmacy and multimorbidity,” investigators stated.

At the outset of the COVID-19 pandemic, there were concerns that patients with rheumatoid arthritis would be more vulnerable due to their condition and its treatment. What impact has the availability of vaccines against COVID-19 had on the vulnerability of patients with rheumatoid arthritis? Test your knowledge with this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 9, 2022.

The survey found 42% of patients with psoriatic disease had never discussed treatment goals with their provider, and less than half of patients with psoriatic arthritis were treated by a rheumatologist.

“These data suggest that vaccine responses are reduced but can be improved by sufficient vaccine/virus exposure,” investigators stated.

ACR20 response was significantly higher in patients receiving either deucravacitinib 6 mg daily or 12 mg daily when compared with placebo.

Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.

There was an adequate response for pediatric patients on biologics to the H1N1 and H3N2 serotypes.